Medical Information

The differentiation syndrome related to amlodipine requires urgent identification and treatment, hyperbilirubinemia is mostly benign but requires regular monitoring, and appetite loss requires multidisciplinary collaborative management.

1、 Differentiation syndrome (DS)

1.1 Mechanism and Risks of Occurrence

Ensidipine induces differentiation of IDH2 mutant AML cells, which can lead to differentiation syndrome and, in severe cases, can be life-threatening.

1.2 Main clinical manifestations

Fever (body temperature ≥ 38.5 ℃), difficulty breathing, and low blood pressure.

Pulmonary infiltration, pleural or pericardial effusion.

Peripheral edema and rapid weight gain (≥ 5kg/3 days).

Abnormal function of multiple organs such as liver and kidney.

1.3 Processing Strategy

Once DS is suspected: Immediately administer dexamethasone 10mg q12h (or equivalent glucocorticoid) for at least 3 days, gradually reducing dosage after symptom relief.

Suspend medication: If symptoms persist or worsen, Ensidipine should be temporarily suspended and evaluated for recovery after DS remission to ≤ grade 1.

Preventive medication: In subsequent treatment courses, early administration of corticosteroids can be considered to reduce the risk of recurrence.

2、 Hyperbilirubinemia

2.1 Characteristics of occurrence

Enzidipine interferes with bilirubin metabolism, leading to an increase in unconjugated bilirubin, but usually without a significant increase in transaminases, indicating non liver cell damaging jaundice.

2.2 Differential diagnosis

It needs to be differentiated from drug-induced liver injury, biliary obstruction, hemolysis, etc.

If AST/ALT levels significantly increase synchronously (>3 × ULN), liver toxicity should be monitored and evaluated in a timely manner.

2.3 Management Suggestions

Regular monitoring: Liver function (total bilirubin, ALT, AST, alkaline phosphatase) should be rechecked every 2 weeks before and during treatment.

Dose adjustment:

Bilirubin>3 × ULN: Suspend medication and restart at 100mg/day after recovery to ≤ 2 × ULN.

If it rises again above 3 × ULN, consider reducing it to 50mg/day.

3、 Decreased appetite

3.1 Performance and Impact

The incidence of appetite loss in clinical studies is about 15% to 20%, which can lead to weight loss, malnutrition, and affect treatment tolerance and quality of life.

3.2 Intervention Measures

Dietary adjustment: Eat small meals multiple times and choose high protein, high calorie foods (such as eggs, fish, nuts, and whole milk products).

Nutritional supplementation: Oral nutritional supplements (ONS), with necessary consultation from the nutrition department.

Symptomatic treatment: If combined with nausea or taste changes, antiemetic drugs can be added or the medication time can be adjusted (such as taking before bedtime).

Monitoring weight: Weigh once a week. If the weight drops by more than 5% within one month, active nutritional intervention should be taken to rule out other causes.